Episode 150: The Cost of MS Medications, Drug Development, and More: My Conversation with Genentech CEO Alexander Hardy
RealTalk MS13 Jul 2020

Episode 150: The Cost of MS Medications, Drug Development, and More: My Conversation with Genentech CEO Alexander Hardy

Conversations about MS almost always get around to the high cost of MS disease-modifying therapies. Joining me on the podcast is the CEO of Genentech, Alexander Hardy. Genentech is a biotech company that many of you know as the manufacturer of Ocrevus, the first approved disease-modifying therapy that treats both relapsing-remitting MS and primary progressive MS. During our wide-ranging conversation, Alexander and I get into the cost of MS prescription medications, the real costs of bringing a new drug to market, racial disparities in clinical trials, inequities in our healthcare system, and more. It's a conversation that you won't want to miss. We'll also tell you where you can get a FREE copy of Dr. Brandon Beaber's book, Resilience in the Face of Multiple Sclerosis, and where to sign up for the next series of Virtual Jumpstart programs from CAN-DO MS. We'll even share the details about this Sunday's Longest Day of Golf, a creative (and very successful!) DIY fundraising event for the National MS Society. We're also talking about a newly published study that shows that most relapsing-remitting MS disability accumulation is progressive and not tied to relapses. And we'll tell you about another study that shows that most people living with MS want to discuss the cost of their treatment with their neurologist, but very few do. We'll even share our thoughts about how we can begin to fix this. We have a lot to talk about! Are you ready for RealTalk MS??!

It's Our 150th Episode! :22

Get in Touch with RealTalk MS 1:36

Get Your Free Copy of Resilience in the Face of Multiple Sclerosis 3:34

CAN-DO MS Virtual Jumpstart Programs 4:43

The Longest Day of Golf Fundraising Event for the National MS Society 5:38

Study Finds Most Relapsing-Remitting MS Disability Accumulation Is Progressive and Not Tied to Relapses 7:29

Survey Shows Most MS Patients Want to Discuss the Cost of MS Care...But Don't 9:50

"Patients" are Customers! 11:31

My Interview with Alexander Hardy 13:09

Share this episode 29:31

Please Support the National MS Society COVID-19 Response Fund 29:50

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/150

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

National MS Society's Ask An MS Expert Video Replay

What You Need to Know About Coronavirus (COVID-19)

National MS Society COVID-19 Response Fund

To receive a free copy of Resilience in the Face of Multiple Sclerosis, just jump onto Twitter, and request your copy by sending a Tweet to the author, @Brandon_Beaber.

CAN-DO MS Virtual Jumpstart Programs

Longest Day of Golf Fundraising Event for the National MS Society

STUDY: Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

STUDY: Perceptions and Experiences of Multiple Sclerosis Patients Regarding Out-of-Pocket Costs of Care Discussions

Join the RealTalk MS Facebook Group

Download the RealTalk MS App for iOS

Download the RealTalk MS App for Android

Give RealTalk MS a Rating and Review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 150
Hosted By: Jon Strum
Guests: Alexander Hardy

Tags: MS, MultipleSclerosis, MSResearch, MSSociety, Genentech, Ocrevus, Resilience, RealTalkMS

Privacy Policy

Episoder(505)

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with ...

23 Feb 35min

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest...

16 Feb 44min

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the A...

9 Feb 33min

Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investig...

2 Feb 39min

Episode 439: Preventing MS with Dr. Bruce Bebo

Episode 439: Preventing MS with Dr. Bruce Bebo

The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Offi...

26 Jan 32min

Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi

Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi

One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they iden...

19 Jan 29min

Episode 437: Remembering David Mitchell

Episode 437: Remembering David Mitchell

I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medicati...

12 Jan 29min

Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman

Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman

Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS ...

5 Jan 34min

Populært innen Helse

fastlegen
rss-gukild-johaug
hvordan-har-du-det-mann
lydartikler-fra-aftenposten
psykodrama
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-garne-damer
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
foreldreradet
hormonelle-frida
g-punktet
hjernesterk
rss-lopedrommen
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
biohacking-girls-din-podcast-for-optimal-helse
helsetipspodden
treningsprat
sinnsyn